QLGN: Qualigen Therapeutics, Inc. Stock

by  •  • Comments Off on QLGN: Qualigen Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 2.37
Enterprise Value ($M) 3.42
Book Value ($M) -2.14
Book Value / Share -2.91
Price / Book -1.11
NCAV ($M) -2.14
NCAV / Share -2.91
Price / NCAV -1.11

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -3.86
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.52
Current Ratio 0.52

Balance Sheet (mrq) ($M)
Current Assets 2.31
Assets 2.31
Liabilities 4.45
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S
2024-07-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-17 289 1,180 24.49
2025-04-16 8,212 75,304 10.91
2025-04-15 1,250 7,242 17.26
2025-04-14 9,907 30,372 32.62

(click for more detail)

Similar Companies
PTIX – Protagenic Therapeutics, Inc. PTPI – Petros Pharmaceuticals, Inc.
PULM – Pulmatrix, Inc. QTTB – Q32 Bio Inc.
RENB – Renovaro Inc.


Financial data and stock pages provided by
Fintel.io